Steris Plc (NYSE:STE) VP John Adam Zangerle sold 3,650 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Steris Plc (STE) traded down $0.04 during trading on Friday, hitting $87.85. 245,510 shares of the company’s stock traded hands, compared to its average volume of 471,007. Steris Plc has a one year low of $64.37 and a one year high of $93.39. The firm has a market cap of $7,510.00, a PE ratio of 22.75 and a beta of 1.31. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18.
Steris Plc (NYSE:STE) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.95 by ($0.01). Steris Plc had a return on equity of 11.49% and a net margin of 5.59%. The firm had revenue of $634.20 million for the quarter, compared to analyst estimates of $629.02 million. During the same period in the prior year, the business earned $0.89 earnings per share. Steris Plc’s revenue for the quarter was down 1.9% on a year-over-year basis. equities research analysts predict that Steris Plc will post 4.06 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Shareholders of record on Wednesday, November 22nd will be paid a dividend of $0.31 per share. The ex-dividend date is Tuesday, November 21st. This represents a $1.24 annualized dividend and a dividend yield of 1.41%. Steris Plc’s dividend payout ratio is currently 73.81%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its position in shares of Steris Plc by 1,972.4% in the second quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock worth $625,880,000 after acquiring an additional 7,308,950 shares during the last quarter. BlackRock Inc. boosted its position in shares of Steris Plc by 33.4% in the second quarter. BlackRock Inc. now owns 7,032,984 shares of the medical equipment provider’s stock worth $573,188,000 after acquiring an additional 1,760,879 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Steris Plc by 1.6% in the second quarter. Vanguard Group Inc. now owns 6,879,760 shares of the medical equipment provider’s stock worth $560,700,000 after acquiring an additional 107,644 shares during the last quarter. FMR LLC boosted its position in shares of Steris Plc by 33.1% in the second quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock worth $281,544,000 after acquiring an additional 859,228 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Steris Plc by 53.2% in the second quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock worth $190,392,000 after acquiring an additional 811,622 shares during the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently commented on the stock. Raymond James Financial, Inc. increased their price objective on shares of Steris Plc from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. TD Securities raised their price target on shares of Steris Plc from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. BidaskClub cut shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research raised shares of Steris Plc from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a research note on Monday, October 9th. Finally, KeyCorp reaffirmed a “buy” rating and set a $91.00 price target on shares of Steris Plc in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Steris Plc currently has an average rating of “Hold” and a consensus target price of $77.80.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.